News
-
-
-
REGULATED PRESS RELEASE
NFL Biosciences presents its 2024 annual results and provides an update on its clinical program
NFL Biosciences presents 2024 annual results and clinical program update. NFL-101 phase 2 efficacy, innovative action with CEA, Phase 3 study plans, financing strategy, low cash burn until Q4 2025 -
-
REGULATED PRESS RELEASE
NFL Biosciences presents the immunological analysis results of its phase 2 CESTO II study confirming the efficacy of NFL-101, its first-in-class treatment for tobacco addiction
NFL Biosciences presents immunological analysis results of phase 2 CESTO II study confirming efficacy of NFL-101 for tobacco addiction. Association between anti-tobacco IgG increase and continuous abstinence strengthens evidence -
-
-
-
REGULATED PRESS RELEASE
NFL Biosciences publishes positive results from a complementary program confirming the excellent safety profile of NFL-101, its first-in-class treatment for tobacco addiction
NFL Biosciences reports positive results from toxicity study on NFL-101, showing superior safety profile for tobacco addiction treatment, enhancing potential for Phase 3 development -
REGULATED PRESS RELEASE
NFL BIOSCIENCES VALIDATES THE INDUSTRIALIZATION OF NFL-101 FOR SMOKING CESSATION
